AEON Biopharma, Inc.
AEON
$0.88
$0.00-0.23%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.21M | 11.35M | 12.06M | 12.12M | 13.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.30M | 16.87M | 17.95M | 21.39M | 27.82M |
| Operating Income | -16.30M | -16.87M | -17.95M | -21.39M | -27.82M |
| Income Before Tax | -39.22M | -3.00K | -1.64M | 169.12M | 42.01M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.22 | 0.00 | -1.64 | 169.12 | 42.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.22M | -3.00K | -1.64M | 169.12M | 42.01M |
| EBIT | -16.30M | -16.87M | -17.95M | -21.39M | -27.82M |
| EBITDA | -16.23M | -16.79M | -17.87M | -21.30M | -27.73M |
| EPS Basic | -1.59 | 5.05 | -5.80 | 298.80 | 68.65 |
| Normalized Basic EPS | -0.23 | -4.65 | -9.37 | -7.85 | -74.34 |
| EPS Diluted | -1.59 | 5.04 | -5.82 | 298.79 | 68.63 |
| Normalized Diluted EPS | -0.23 | -4.64 | -9.36 | -7.83 | -74.33 |
| Average Basic Shares Outstanding | 39.60M | 27.26M | 16.18M | 5.63M | 2.16M |
| Average Diluted Shares Outstanding | 39.60M | 27.27M | 16.18M | 5.63M | 2.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |